Crinetics Pharmaceuticals doses first patient in novel tumor treatment trial
Crinetics Pharmaceuticals has announced a significant milestone with the dosing of the first patient in their Phase 1/2 trial. The trial is focused on evaluating CRN09682, a novel nonpeptide drug ...